Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Avastin in Esophageal or Gastroesophageal Junction Cancer
NCT00442507Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, bevacizumab in esophageal cancer, gastroesophageal junction cancer, sponsored by Washington University School of Medicine. Started Mar 2007; status: terminated.
02
Drugs
erlotinibbevacizumab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00442507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00442507.